Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Atea Pharmaceuticals, Inc. (AVIR : NSDQ)

• Company Description    Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Atea Pharmaceuticals Inc. is based in BOSTON. Number of Employees: 59

• Price / Volume Information    Yesterday's Closing Price: $7.51 Daily Weekly Monthly 20 Day Moving Average: 650,468 shares Shares Outstanding: 83.26 (millions) Market Capitalization: $625.27 (millions) Beta: -0.58 52 Week High: $46.91 52 Week Low: $5.31 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 21.13% 32.72% 12 Week 26.86% 37.65% Year To Date -16.00% -0.10%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 125 SUMMER STREET - BOSTON,MA 02110 USA ph: 857-284-8891 fax: - investors@ateapharma.com http://www.ateapharma.com

• General Corporate Information    Officers Jean-Pierre Sommadossi - President; Chief Executive Officer and Chairman Andrea Corcoran - Chief Financial Officer and Executive Vice Preside Wayne Foster - Executive Vice President; Chief Accounting Officer Franklin Berger - Director Jerome Adams - Director Peer Information Atea Pharmaceuticals, Inc. (CORR.) Atea Pharmaceuticals, Inc. (RSPI) Atea Pharmaceuticals, Inc. (CGXP) Atea Pharmaceuticals, Inc. (BGEN) Atea Pharmaceuticals, Inc. (GTBP) Atea Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04683R106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 83.26 Most Recent Split Date: (:1) Beta: -0.58 Market Capitalization: $625.27 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.56 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.31 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 14.73 PEG Ratio: - Price Ratios Price/Book: 0.92 Price/Cash Flow: 5.15 Price / Sales: 1.78 EPS Growth vs. Year Ago Period: -250.00% vs. Previous Quarter: -138.06% Sales Growth vs. Year Ago Period: 295.16% vs. Previous Quarter: 485.72% ROE 03/31/22 - 7.54 12/31/21 - 19.58 09/30/21 - 4.27 ROA 03/31/22 - 6.04 12/31/21 - 14.56 09/30/21 - 2.89 Current Ratio 03/31/22 - 24.93 12/31/21 - 13.58 09/30/21 - 3.22 Quick Ratio 03/31/22 - 24.93 12/31/21 - 13.58 09/30/21 - 3.22 Operating Margin 03/31/22 - - 12/31/21 - 34.49 09/30/21 - 11.89 Net Margin 03/31/22 - - 12/31/21 - 34.49 09/30/21 - 11.89 Pre-Tax Margin 03/31/22 - 23.06 12/31/21 - 39.44 09/30/21 - 18.29 Book Value 03/31/22 - 8.17 12/31/21 - 8.54 09/30/21 - 7.02 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©